ArticlePLoS neglected tropical diseases2016
Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020Pooled it
- Unlocking Hope: Paving the Way for a Cutting-Edge Multi-Epitope Dengue Virus Vaccine.Molecular biotechnology · 2025Article
- Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference.NPJ vaccines · 2025Article
- Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023Review
- Functional amyloid-chitin hybrid ink coupled with flexible fabrication approaches for diverse macro and micro-structures.Materials today. Bio · 2022Article
- Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Nano-based approaches in the development of antiviral agents and vaccines.Life sciences · 2021Review
- Nanoparticles as Vaccines to Prevent Arbovirus Infection: A Long Road Ahead.Pathogens (Basel, Switzerland) · 2021Review
- Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.Journal of virology · 2020Article
- Retinoic Acid-Loaded Poly(lactic-Journal of biomedical nanotechnology · 2020Article
- Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.mBio · 2019Article
- Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.PLoS neglected tropical diseases · 2018Article
- Bionanotechnology for vaccine design.Current opinion in biotechnology · 2018Review
- Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins.The Journal of biological chemistry · 2018Article
- Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.Virology journal · 2018Article
- Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.Journal of clinical microbiology · 2018Article
- A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Development of Peptide Vaccines in Dengue.Current pharmaceutical design · 2018Review
- In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers.Scientific reports · 2017Article
- Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic fever. The virus is endemic in over 120 countries, causing over 350 million infections per year. Dengue vaccine development is challenging because of the need to induce simultaneous protection against four antigenically distinct DENV serotypes and evidence that, under some conditions, vaccination can enhance disease due to specific immunity to the virus. While several live-attenuated tetravalent dengue virus vaccines display partial efficacy, it has been challenging to induce balanced protective immunity to all 4 serotypes. Instead of using whole-virus formulations, we are exploring the potentials for a particulate subunit vaccine, based on DENV E-protein displayed on nanoparticles that have been precisely molded using Particle Replication in Non-wetting Template (PRINT) technology. Here we describe immunization studies with a DENV2-nanoparticle vaccine candidate. The ectodomain of DENV2-E protein was expressed as a secreted recombinant protein (sRecE), purified and adsorbed to poly (lactic-co-glycolic acid) (PLGA) nanoparticles of different sizes and shape. We show that PRINT nanoparticle adsorbed sRecE without any adjuvant induces higher IgG titers and a more potent DENV2-specific neutralizing antibody response compared to the soluble sRecE protein alone. Antigen trafficking indicate that PRINT nanoparticle display of sRecE prolongs the bio-availability of the antigen in the draining lymph nodes by creating an antigen depot. Our results demonstrate that PRINT nanoparticles are a promising platform for delivering subunit vaccines against flaviviruses such as dengue and Zika.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.